Hereditary Angioedema clinical trials at UCSD

2 in progress, 1 open to eligible people

Showing trials for

  • A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

    open to eligible people ages 18 years and up

    This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.

    San Diego, California and other locations

  • A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

    Sorry, in progress, not accepting new patients

    The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.

    San Diego, California and other locations

Our lead scientists for Hereditary Angioedema research studies include .

Last updated: